App-Quantinova.ai

Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.

- International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

GDNF

Reappraisal of cortical myoclonus: a retrospective study of clinical neurophysiology

A. Latorre - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Regional differences may influence the drivers of change in Toronto Western Spasmodic Rating Scale (TWSTRS) scores following botulinum toxin treatment: Analysis of an international observational study

V. Misra - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Botox

Research participants are not representative of the population age distribution of PD

A. Macleod - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

Screening of GBA and LRRK2 G2019S Mutations in Egyptian Parkinson’s Disease Patients

L. R'Bibo - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study

A.-A. Roussakis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias

A.-A. Roussakis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Ioflupane

Speech difficulties are linked to striatal dopaminergic deficits and cognitive decline in early de novo patients with Parkinson’s disease

S. Polychronis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Structural brain abnormalities associated with preclinical cognitive impairment in Idiopathic Parkinson’s Disease.

C. Lambert - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Mild cognitive impairment

N/A

Successful deep brain stimulation treatment of incapacitating tremor resulting from bilateral thalamic infarcts complicating surgery for Arnold Chiari malformation/syringomyelia.

S. Alusi - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Chiari malformation

N/A

Swallowing difficulties and Parkinson’s disease

S. Polychronis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The Cats & Dogs Test: a web-based platform to detect early visual processing deficits in Parkinson’s disease

R. Weil - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The effect of deep brain stimulation in a computational model of essential tremor

N. Yousif - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Essential tremor

N/A

The effects of wearing usual indoor and outdoor footwear on balance and gait performance in people with Parkinson’s disease using clinical tests and instrumented movement analysis.

D. Kunkel - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Parkinson's disease

Pamicogrel

The impact of divided attention in dual task conditions on drooling in Parkinson’s Disease (PD): a pilot study

H. Reynolds - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The role of phosphodiesterase 4 in sleep disturbances in Parkinson’s disease

H. Wilson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Rolipram

Time to retreatment with botulinum toxin A in upper limb spasticity management: initial data from the Upper Limb International Spasticity (ULIS)-III study

L. Turner-Stokes - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Botulinum toxin A

Translating the Parkinson´s Disease Sleep Scale (PDSS-2) into 31 Languages Using a Standardized Methodology

K.R. Chaudhuri - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Tremor in motorneuron disease: central or peripheral origin?

A. Latorre - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Orphenadrine Citrate

Using the power of a Network to accomplish a Countrywide Review of Acute Parkinson’s Disease management

E. Peter - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Methadone hydrochloride

Filters

45280 Abstracts